COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04401150

Not reported

Not reported

2020-05-26

Completed

RCT

Randomized

Parallel

Blind label

multi-center

Treatment

inclusion criteria: - confirmed diagnosis of covid-19; - admitted to hospital (ward or intensive care unit).

- receiving or has received vasopressors during the current hospitalization; - more than 24 hours has elapsed since receipt of non-invasive ventilatory support (high-flow nasal cannula or continuous positive airway pressure or non-invasive ventilation) or invasive mechanical ventilation; - patient is expected to be discharged from the hospital in the next 24 hours; - more than 14 days have elapsed since the commencement of hospital admission with respiratory illness; - known glucose-6-phosphate dehydrogenase (g6pd) deficiency; - known sickle cell anemia - pregnancy or breastfeeding; - known allergy to vitamin c; - known kidney stones within the past 1 year; - received any intravenous vitamin c during this hospitalization unless incorporated in parenteral nutrition; - expected death or withdrawal of life-sustaining treatments within 48 hours; - previously enrolled in this study; - previously enrolled in a trial for which co-enrolment is not allowed (co- enrolment to be determined case by case). the trial has broad eligibility criteria and includes all covid-19 patients admitted to the hospital (e.g. hospital ward or the intensive care unit) who are not receiving vasopressors.

2

Université de Sherbrooke

18

100

Canada

Moderate/severe/critical disease at enrollment

5: Moderate/severe/critical disease at enrollment

392

Death or persistent organ dysfunction

None

Phase 3

[{"arm_notes": "", "treatment_id": 1369, "treatment_name": "Vitamin c", "treatment_type": "Vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]